As we age, the brain gets less
efficient and forgetfulness increases by leaps and bounds. Acquiring
Alzheimer’s disease or Parkinsonism is not the case always but certain other
degenerative proteins cite actions that decrease the brain efficiency. It is
the cholinergic and dopaminergic neurons that begin the deleterious effect on
the memory. Since the cholinergic neurotransmitters govern the actions at the
basal ganglia of the brain, the neurodegenerative changes through normal aging
begin their action.
Along with aging, the brain cells
start being damaged and give rise to various mental disorders. No such
medication has been invented that may completely cure the following ailments
but delay the process. Similarly, aging can never be stopped but the
consequences can be slowed down.
In the article Gene Therapy and Cell
Reprogramming For the Aging Brain: Achievements and Promise
the author has discussed aging and the effects of cholinergic and dopaminergic
agonists and antagonists in a vast perspective. The article also features
modification of cells with age and the mal-effects on diabetic patients. The
journal Current Gene Therapy focuses
on the gene and cell therapy. Moreover, the research tells much about the experimental
evidence supporting the neuroprotective relevance of these and related factors
in the aging brain.